drugset / Trial / NCT05823896

ImPROving Quality of LIFe in the Long COVID Patient

NCT05823896

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to investigate the efficacy of orally administered nirmatrelvir/ritonavir compared with placebo/ritonavir to improve quality of life in non-hospitalized adult participants suffering from post-acute COVID-19 syndrome.

Timeline

Start
2023-05-01
Primary completion
2024-11-28
Completion
2024-11-28

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Nirmatrelvir Small molecule 300 mg Oral
Comparator Ritonavir Other / unclassified 100 mg Oral